Clinical trials: Rosuvastatin
Hypercholesterolemia
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT)…
- Trial name
- NCT02289963
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 27 sites in South Korea, Taiwan
- Volunteers
- 199 people
- Sponsor
- Sanofi
Ischemic Stroke, Atherosclerosis of Artery
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
The goal of this clinical trial is to evaluate whether the combination of Probucol with statin therapy can reduce the risk of vascular events and improve atherosclerosis outcomes in adults with ischemic stroke and confirmed…
- Conditions
- Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder, Statin
- Trial name
- EPCIS (NCT06604117)
- Testing
- Statin, Probucol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xuanwu Hospital, Beijing
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
cMET-dysregulated Advanced Solid Tumors
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
- Trial name
- NCT02626234
- Testing
- INC280, digoxin, rosuvastatin
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant.
- Trial name
- NCT05912387
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy
Drug Interaction Study of Clopidogrel and Rosuvastatin
The purpose of this study is to determine if clopidogrel inhibits hepatic uptake transport of rosuvastatin clinically.
- Trial name
- NCT01469416
- Testing
- Rosuvastatin, Clopidogrel
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Drug Interaction Potentiation
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
This is a Phase 1, three-part, open-label study to evaluate vadadustat as a perpetrator in drug-drug interactions with rosuvastatin, sulfasalazine, pravastatin, atorvastatin and simvastatin in healthy male and female subjects.
- Trial name
- NCT03801733
- Testing
- Vadadustat, Simvastatin, Rosuvastatin
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Contrast-induced Acute Kidney Injury, ST Elevation Myocardial Infarction
A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI
The CIAKI,as the third complication of PCI, was associated with adverse cardiac events after procedure. Moreover, because the rate of periprocedure hydration is inadequate in STEMI patients before primary PCI, the incidence of…
- Conditions
- Contrast-induced Acute Kidney Injury, ST Elevation Myocardial Infarction, Primary PCI, Rosuvastatin
- Trial name
- TRACK-AMI (NCT03526367)
- Testing
- hydration plus rosuvastatin therapy, Standard therapy
- Where
- China
- Sponsor
- Shenyang Northern Hospital
Healthy
A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects
The purpose of this study is to investigate the effect of MT-8554 on the pharmacokinetics of simvastatin and rosuvastatin in healthy subjects.
- Trial name
- NCT02675309
- Testing
- MT-8554, rosuvastatin, simvastatin
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Health, Subjective
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers
This is a two-arm, open-label, single-sequence, multiple-dose, cross-over phase 1 study to evaluate the interaction between two investigational drugs by comparing and analyzing the pharmacokinetic interaction and safety of…
- Trial name
- NCT05002244
- Testing
- CTL0801 (Azilsartan), CTL0802 (Rosuvastatin), CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Celltrion
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary…
- Trial name
- RODEO (NCT00929734)
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 99 people
- Sponsor
- University Hospital, Akershus
Hypercholesterolemia
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
- Trial name
- NCT00240279
- Testing
- Rosuvastatin, aortic pulse wave velocity measurements
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Fruquintinib DDI Study With P-gp and BCRP Substrates
Fruquintinib DDI Study with P-gp and BCRP Substrates
- Trial name
- NCT05368805
- Testing
- Fruquintinib, Dabigatran Etexilate, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Hypercholesterolemia, Coronary Heart Disease
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg
The purpose of this study is to compare 6 weeks of treatment with rosuvastatin alone compared with 6 weeks of treatment of rosuvastatin combined with ezetimibe in achieving low density lipoprotein level goals.
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
- Trial name
- EXPLORER (NCT00653445)
- Testing
- Rosuvastatin, Ezetimibe
- Sponsor
- AstraZeneca
Hypertension, Hyperlipidemias
DP-R212 Pharmacokinetic Study
An open-label, multiple-dose study to evaluate the pharmacokinetic drug-drug interaction of amlodipine and rosuvastatin in healthy adult male subjects.
- Trial name
- NCT02789475
- Testing
- Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
Blunt Chest Trauma, Acute Respiratory Distress Syndrome
Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma
Background: Lung contusion affects 17%-25% of adult blunt trauma patients, and is the leading cause of death from blunt thoracic injury.
- Trial name
- NCT01623921
- Testing
- standard care treatment, Celecoxib, Rosuvastatin
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hypertension, Hyperlipidemia
Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg
To compare the safety and pharmacokinetics between ROVATITAN tab. 160/20 mg (ROVATITAN tab 160/20mg-1, ROVATITAN tab. 160/20mg-2) and coadministration of Diovan® (Valsartan) 160 mg and Crestor® (Rosuvastatin) 20 mg in healthy…
- Trial name
- NCT01918358
- Testing
- Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R), Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1), Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Healthy Volunteers
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy…
- Trial name
- NCT07446400
- Testing
- Repinatrabit, EE/NE, Metformin
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acute Coronary Syndrome
Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in ACS Patients
The purpose of this study is to determine whether Rosuvastatin 10mg/d or 20mg/d for 36 weeks can regress critical coronary atherosclerosis as determined by IVUS imaging in Chinese Acute Coronary Syndrome (ACS) patients.
- Trial name
- NCT02420899
- Testing
- rosuvastatin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Friendship Hospital
Carotid Artery Stenosis, Strokes
Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes
The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA…
- Trial name
- STANCE (NCT02850081)
- Testing
- Statin, Atorvastatin
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Columbia University